TARA Protara Therapeutics Inc
Price (delayed)
$4.29
Market cap
$157.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.17
Enterprise value
-$582,575
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based
Highlights
The equity has surged by 145% year-on-year and by 104% since the previous quarter
Protara Therapeutics's quick ratio has soared by 65% from the previous quarter and by 46% YoY
The company's net income fell by 10% YoY and by 6% QoQ
Key stats
What are the main financial stats of TARA
Market
Valuations
Earnings
Shares outstanding
36.77M
Market cap
$157.73M
Enterprise value
-$582,575
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$49.15M
Net income
-$44.6M
EBIT
-$44.6M
EBITDA
-$44.26M
Free cash flow
-$35.87M
Per share
Balance sheet
Liquidity
EPS
-$2.17
EPS diluted
-$2.17
Free cash flow per share
-$1.74
Book value per share
$8.1
Revenue per share
$0
TBVPS
$8.81
Total assets
$181.45M
Total liabilities
$14.32M
Debt
$4.48M
Equity
$167.13M
Working capital
$161.19M
Debt to equity
0.03
Current ratio
15.71
Quick ratio
15.54
Net debt/EBITDA
3.58
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-40.1%
Return on equity
-44.7%
Return on invested capital
-229.8%
Return on capital employed
-26.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TARA stock price
How has the Protara Therapeutics stock price performed over time
Intraday
6.98%
1 week
-5.3%
1 month
14.71%
1 year
4.38%
YTD
-18.75%
QTD
0.7%
Financial performance
How have Protara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.15M
Net income
-$44.6M
Gross margin
N/A
Net margin
N/A
TARA's operating income is down by 13% year-on-year and by 7% since the previous quarter
The company's net income fell by 10% YoY and by 6% QoQ
Growth
What is Protara Therapeutics's growth rate over time
Valuation
What is Protara Therapeutics stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 39% year-on-year and by 23% since the previous quarter
The equity has surged by 145% year-on-year and by 104% since the previous quarter
TARA's P/B is 18% below its 5-year quarterly average of 0.6 and 18% below its last 4 quarters average of 0.6
Efficiency
How efficient is Protara Therapeutics business performance
TARA's return on invested capital is down by 42% since the previous quarter
TARA's ROE is up by 20% since the previous quarter and by 10% year-on-year
The ROA has grown by 18% from the previous quarter and by 8% YoY
Dividends
What is TARA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TARA.
Financial health
How did Protara Therapeutics financials performed over time
The total assets has surged by 130% year-on-year and by 93% since the previous quarter
Protara Therapeutics's quick ratio has soared by 65% from the previous quarter and by 46% YoY
The debt is 97% less than the equity
The equity has surged by 145% year-on-year and by 104% since the previous quarter
Protara Therapeutics's debt to equity has plunged by 63% YoY and by 50% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.